Association between programmed death-1 pathway and major depression

References

• Bardhan K, Anagnostou T, Boussiotis VA. 2016. The PD1: PD-L1/2 pathway from discovery to clinical implementation. Front Immunol. 7:550–550. eng.
   PubMed Web of Science ®Google Scholar
• Beck AT, Kovacs M, Weissman A. 1979. Assessment of suicidal intention: the scale for suicide ideation. J Consult Clin Psychol. 47(2):343–352. eng.
   PubMed Web of Science ®Google Scholar
• Berthold-Losleben M, Himmerich H. 2008. The TNF-alpha system: functional aspects in depression, narcolepsy and psychopharmacology. Curr Neuropharmacol. 6(3):193–202.
   PubMed Web of Science ®Google Scholar
• Birkenhager TK, Geldermans S, Van den Broek WW, van Beveren N, Fekkes D. 2012. Serum brain-derived neurotrophic factor level in relation to illness severity and episode duration in patients with major depression. J Psychiatr Res. 46(3):285–289. English.
   PubMed Web of Science ®Google Scholar
• Butler AM, Malone K. 2013. Attempted suicide v. non-suicidal self-injury: behaviour, syndrome or diagnosis? Br J Psychiatry. 202(5):324–325. eng.
   PubMed Web of Science ®Google Scholar
• Chamoto K, Al-Habsi M, Honjo T. 2017. Role of PD-1 in immunity and diseases. Curr Top Microbiol Immunol. 410:75–97. eng.
   PubMed Web of Science ®Google Scholar
• Dwivedi Y. 2009. Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr Dis Treat. 5:433–449. eng.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. 2010. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 236:219–242. eng.
   PubMed Web of Science ®Google Scholar
• Fries GR, Saldana VA, Finnstein J, Rein T. 2023. Molecular pathways of major depressive disorder converge on the synapse. Mol Psychiatry. 28(1):284–297.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. 2015. Pembrolizumab for the treatment of non–Small-Cell lung cancer. N Engl J Med. 372(21):2018–2028.
   PubMed Web of Science ®Google Scholar
• Giordano M, Roncagalli R, Bourdely P, Chasson L, Buferne M, Yamasaki S, Beyaert R, van Loo G, Auphan-Anezin N, Schmitt-Verhulst AM, et al. 2014. The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proc Natl Acad Sci USA. 111(30):11115–11120. eng.
   PubMed Web of Science ®Google Scholar
• Gupta K, Gupta R, Bhatia MS, Tripathi AK, Gupta LK. 2017. Effect of agomelatine and fluoxetine on HAM-D score, serum brain-derived neurotrophic factor, and tumor necrosis factor- level in patients with major depressive disorder with severe depression. J Clin Pharmacol. 57(12):1519–1526. English.
   PubMed Web of Science ®Google Scholar
• Gupta R, Gupta K, Tripathi AK, Bhatia MS, Gupta LK. 2016. Effect of mirtazapine treatment on serum levels of brain-derived neurotrophic factor and tumor necrosis factor-alpha in patients of major depressive disorder with severe depression. Pharmacology. 97(3-4):184–188. English.
   PubMed Web of Science ®Google Scholar
• Hamilton M. 1967. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 6(4):278–296. eng.
   PubMedGoogle Scholar
• Huang TL, Cho YT, Su H, Shiea J. 2013. Principle component analysis combined with matrix-assisted laser desorption ionization mass spectrometry for rapid diagnosing the sera of patients with major depression. Clin Chim Acta. 424:175–181.
   PubMed Web of Science ®Google Scholar
• Huang TL, Hung YY. 2009. Lorazepam reduces the serum brain-derived neurotrophic factor level in schizophrenia patients with catatonia. Prog Neuro-Psychopharmacol Biolo Psychiatry. 33(1):158–159.
   PubMed Web of Science ®Google Scholar
• Huang TL, Lee CT. 2006. Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J Psychiatr Res. 40(7):664–668.
   PubMed Web of Science ®Google Scholar
• Huang TL, Lee CT, Liu YL. 2008. Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. J Psychiatr Res. 42(7):521–525. English.
   PubMed Web of Science ®Google Scholar
• Huang TL, Lin CC, Chen RF, Lee CT. 2016. Higher blood MLL1 mRNA and BDNF promoter IV on histone H3K4me3 levels in patients with schizophrenia. Psychiatry Res. 243:207–209.
   PubMed Web of Science ®Google Scholar
• Hung YY, Lin CC, Kang HY, Huang TL. 2017. TNFAIP3, a negative regulator of the TLR signaling pathway, is a potential predictive biomarker of response to antidepressant treatment in major depressive disorder. Brain Behav Immun. 59:265–272.
   PubMed Web of Science ®Google Scholar
• Hung YY, Yang PS, Huang TL. 2006. Clozapine in schizophrenia patients with recurrent catatonia: report of two cases. Psychiatry Clin Neurosci. 60(2):256–258.
   PubMed Web of Science ®Google Scholar
• Korman AJ, Peggs KS, Allison JP. 2006. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 90:297-339. eng.
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2(3):261–268.
   PubMed Web of Science ®Google Scholar
• Lee BH, Park YM, Um TH, Kim S. 2014. Lower serum brain-derived neurotrophic factor levels are associated with failure to achieve remission in patients with major depression after escitalopram treatment. Neuropsychiatr Dis Treat. 10:1393–1398. English.
   PubMed Web of Science ®Google Scholar
• Levey DF, Stein MB, Wendt FR, Pathak GA, Zhou H, Aslan M, Quaden R, Harrington KM, Nuñez YZ, Overstreet C, et al. 2021. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nat Neurosci. 24(7):954–963. eng.
   PubMed Web of Science ®Google Scholar
• Levite M. 2021. T cells plead for rejuvenation and amplification; with the brain’s neurotransmitters and neuropeptides we can make it happen. Front Immunol. 12:617658. English.
   PubMed Web of Science ®Google Scholar
• Lian YJ, Gong H, Wu TY, Su WJ, Zhang Y, Yang YY, Peng W, Zhang T, Zhou JR, Jiang CL, et al. 2017. Ds-HMGB1 and fr-HMGB induce depressive behavior through neuroinflammation in contrast to nonoxid-HMGB1. Brain Behav Immun. 59:322–332. eng.
   PubMed Web of Science ®Google Scholar
• Lin CC, Huang TL. 2020. Brain-derived neurotrophic factor and mental disorders. Biomed J. 43(2):134–142.
   PubMed Web of Science ®Google Scholar
• Lu C, Paschall AV, Shi H, Savage N, Waller JL, Sabbatini ME, Oberlies NH, Pearce C, Liu K. 2017. The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion. JNCI J Natl Cancer Inst. 109(6):djw283. eng.
   Web of Science ®Google Scholar
• Martin-Orozco N, Wang Y-H, Yagita H, Dong C. 2006. Cutting edge: programed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue Antigens1. J Immunol. 177(12):8291–8295.
   PubMed Web of Science ®Google Scholar
• Mathios D, Ruzevick J, Jackson CM, Xu H, Shah SR, Taube JM, Burger PC, McCarthy EF, Quinones-Hinojosa A, Pardoll DM, et al. 2015. PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. J Neurooncol. 121(2):251–259. eng.
   PubMed Web of Science ®Google Scholar
• Momtaz P, Postow MA. 2014. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med. 7:357–365. eng.
   PubMedGoogle Scholar
• Nie X, Chen W, Zhu Y, Huang B, Yu W, Wu Z, Guo S, Zhu Y, Luo L, Wang S, et al. 2018. B7-DC (PD-L2) costimulation of CD4(+) T-helper 1 response via RGMb. Cell Mol Immunol. 15(10):888–897. eng.
   PubMed Web of Science ®Google Scholar
• Nomoto H, Baba H, Satomura E, Maeshima H, Takebayashi N, Namekawa Y, Suzuki T, Arai H. 2015. Serum brain-derived neurotrophic factor levels and personality traits in patients with major depression. Bmc Psychiatry. 15(1):33. English.
   PubMedGoogle Scholar
• Orsolini L, Pompili S, Tempia Valenta S, Salvi V, Volpe U. 2022. C-Reactive protein as a biomarker for major depressive disorder? Int J Mol Sci. 23(3):1616. eng.
   PubMed Web of Science ®Google Scholar
• Pariante CM. 2017. Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. Eur Neuropsychopharmacol. 27(6):554–559. eng.
   PubMed Web of Science ®Google Scholar
• Petralia MC, Mazzon E, Fagone P, Basile MS, Lenzo V, Quattropani MC, Di Nuovo S, Bendtzen K, Nicoletti F. 2020. The cytokine network in the pathogenesis of major depressive disorder. Close to translation? Autoimmun Rev. 19(5):102504. eng.
   PubMed Web of Science ®Google Scholar
• Philips EA, Garcia-España A, Tocheva AS, Ahearn IM, Adam KR, Pan R, Mor A, Kong XP. 2020. The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals. J Biol Chem. 295(14):4372–4380. eng.
   PubMed Web of Science ®Google Scholar
• Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmächer T. 2001. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 58(5):445–452. eng.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. 2015. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 372(4):320–330.
   PubMed Web of Science ®Google Scholar
• Syn NL, Teng MWL, Mok TSK, Soo RA. 2017. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 18(12):e731–e741. eng.
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. 2012. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 4(127):127ra137–127ra137.
   Web of Science ®Google Scholar
• Topalian SL, Taube JM, Pardoll DM. 2020. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 367(6477):eaax0182. eng.
   PubMed Web of Science ®Google Scholar
• Tseng S-Y, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, Shalabi A, Shin T, Pardoll DM, Tsuchiya H. 2001. B7-Dc, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med. 193(7):839–846.
   PubMed Web of Science ®Google Scholar
• Wu W, Zheng YL, Tian LP, Lai JB, Hu CC, Zhang P, Chen JK, Hu JB, Huang ML, Wei N, et al. 2017. Circulating T lymphocyte subsets, cytokines, and immune checkpoint inhibitors in patients with bipolar II or major depression: a preliminary study. Sci Rep. 7:40530. eng.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Yu S, Zhu B, Bedoret D, Bu X, Francisco LM, Hua P, Duke-Cohan JS, Umetsu DT, Sharpe AH, et al. 2014. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med. 211(5):943–959.
   PubMed Web of Science ®Google Scholar
• Zhang YQ, Zhang CS, Cheng ZH, Xu WW, Liu XW, Xu Q, Wang Y, Li GL, Ling Y, Zhu J. 2015. Serum levels of brain-derived neurotrophic factor and clinical efficacy of mirtazapine in geriatric patients with major depression. Biomed Res-India. 26(2):338–342. English.
   Google Scholar
• Zhao Q, Xiao X, Wu Y, Wei Y, Zhu LY, Zhou J, Kuang DM. 2011. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol. 41(8):2314–2322. eng.
   PubMed Web of Science ®Google Scholar